{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:12:02Z","timestamp":1792001522950,"version":"4.4.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T00:00:00Z","timestamp":1410739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Woolf-Toomim Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2015,1,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Previous studies have reported additional cancers associated with <jats:italic>BRCA<\/jats:italic> mutations; however, the type, magnitude of risk, and sex differences remain to be clarified. The purpose of this study was to evaluate the incidence of cancers other than breast and ovarian cancer in known mutation carriers.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>An institutional review board\u2013approved study identified 1072 patients who had genetic counseling at the authors' institution and tested positive for a deleterious <jats:italic>BRCA<\/jats:italic> mutation. The expected number of cancer cases was calculated from the number of individuals in the study sample multiplied by the cancer incidence rates for the general population. The expected and observed numbers of cases were calculated in 5\u2010year intervals to accommodate different age\u2010related incidence rates. Standardized incidence ratios (SIRs) for each cancer type were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Among the 1072 mutation carriers, 1177 cancers of 30 different cancer types were identified. Individuals with a <jats:italic>BRCA1<\/jats:italic> mutation did not have a significant increase in cancers other than breast and ovarian cancer; however, a trend in melanoma was observed. Individuals with a <jats:italic>BRCA2<\/jats:italic> mutation had significantly higher numbers of observed cases versus expected cases for pancreatic cancer in both men and women (SIR, 21.7; 95% confidence interval [CI], 13.1\u201034.0; <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001) and for prostate cancer in men (SIR, 4.9; 95% CI, 2.0\u201010.1; <jats:italic>P<\/jats:italic>\u2009=\u2009.002).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The results of this study uphold the current recommendations for hereditary breast and ovarian cancer screening of cancers other than breast and ovarian cancer by the National Comprehensive Cancer Network. Larger cohorts and collaborations are needed to further verify these findings. <jats:bold><jats:italic>Cancer<\/jats:italic> 2015;121:269\u201375<\/jats:bold>. \u00a9 <jats:italic>2014 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.29041","type":"journal-article","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T15:50:12Z","timestamp":1410796212000},"page":"269-275","source":"Crossref","is-referenced-by-count":450,"title":["Cancers associated with <scp><i>BRCA<\/i><\/scp><i>1<\/i> and <scp><i>BRCA<\/i><\/scp><i>2<\/i> mutations other than breast and ovarian"],"prefix":"10.1002","volume":"121","author":[{"given":"Jacqueline","family":"Mersch","sequence":"first","affiliation":[{"name":"Genetic Counseling Program University of Texas Graduate School of Biomedical Science at Houston Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjeong","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Quantitative Sciences University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Nebgen","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology and Reproductive Medicine University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Singletary","sequence":"additional","affiliation":[{"name":"Department of Pediatrics University of Texas Medical School at Houston Houston Texas"},{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences University of Texas Medical School at Houston Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu K.","family":"Arun","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Litton","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7545954"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/378789a0"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/375033"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6772"},{"key":"e_1_2_7_6_1","first-page":"265","article-title":"Breast and ovarian cancer incidence in BRCA1\u2010mutation carriers. Breast Cancer Linkage Consortium","volume":"56","author":"Easton DF","year":"1995","journal-title":"Am J Hum Genet"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/301749"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh474"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2012.15.3.283"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91578-4"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.18.1358"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-011-9506-2"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.18.1365"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.483"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.741"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.15.1310"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.028829"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/513891"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm203"},{"key":"e_1_2_7_20_1","volume-title":"United States Cancer Statistics: 1999\u20102010 Incidence and Mortality Web\u2010Based Report","author":"US Cancer Statistics Working Group","year":"2013"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2005.10.001"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61416-0"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70445-7"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","unstructured":"ShuCA PikeM JotwaniAR et al. Risk of developing uterine corpus cancer (Ut Ca) following risk\u2010reducing salpingo\u2010oophorectomy (RRSO) in women withBRCAmutations. Paper presented at: SGO Annual Meeting; March 24 2014; Tampa Fla.","DOI":"10.1016\/j.ygyno.2014.07.082"},{"key":"e_1_2_7_25_1","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High\u2010Risk Assessment: Breast and Ovarian. Version 1.2014. Fort Washington PA: National Comprehensive Cancer Network; 2014. NCCN Clinical Practice Guidelines in Oncology."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.01.005"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303108"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1966"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29041","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29041","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:51:57Z","timestamp":1760298717000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,15]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1,15]]}},"alternative-id":["10.1002\/cncr.29041"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29041","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,15]]}}}